Visit Janssen With Me
open

Janssen collaborations & initiatives

Janssen & Multiple Myeloma

Janssen’s goal is to fundamentally alter the way cancer is understood, diagnosed and managed. We are committed to finding innovative ways to fight cancer, including for multiple myeloma, and our primary efforts focus on treatment and prevention solutions.

We are driven by our commitment to patients, working side-by-side with healthcare stakeholders, to offer solutions based on trust and transparency. Below are a number of Janssen initiatives that you may find interesting or helpful.

My Myeloma - Ready for the Steps Ahead

My Myeloma - Ready for the Steps Ahead is a documentary that captures the journey of multiple myeloma patients from the Central European and Baltics region. It was filmed in partnership with multiple myeloma patient organisations from Hungary, Croatia, Slovakia, Serbia and Slovenia. It is a heartfelt tribute to the patients, patient organisations and healthcare professionals who have battled tirelessly against this disease.

Finding the Cure: Exploring the potential of MRD as a novel endpoint

Measurable or minimal residual disease (MRD) refers to the small number of myeloma cells that may remain in your bone marrow following treatment; it plays an important role in monitoring remission status.

In the MRD document, leading physicians, together with patients and patient advocates, explore the potential of MRD as a new study endpoint to measure functional cure, sharing their perspectives on the important role it could play in the management and treatment of multiple myeloma. Click here to watch the documentary now.

References

[1]
Myasthenia Gravis Foundation of America (MGFA). A Manual for the Healthcare Provider. Available at: https://myasthenia.org/Portals/0/Provider%20Manual_ibook%20version.pdf Last accessed: June 2024.
[2]
National Institute of Neurological Disorders and Stroke (NINDS). Myasthenia Gravis. Available at: https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis Last accessed: June 2024.
[3]
Dewilde S, et al. People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies. Adv Ther. Vol 40, 4377–4394 (2023). Available at: https://doi.org/10.1007/s12325-023-02604-z Last accessed: June 2024.
[4]
Mahic, et al. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disorders (2023). Available at: https://doi.org/10.1177/17562864221150327 Last accessed: June 2024.
[5]
Daum P et al. Perioperative management of myasthenia gravis. BJA Education (2021) 21(11): 414e419
[6]
John Hopkins Medicine. Myasthenia Gravis. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/myasthenia-gravis Last accessed: June 2024.
[7]
Mishra A, et al. Myasthenia Gravis: A Systematic Review. Cureus (2023) 15(12): e50017. DOI 10.7759/cureus.50017.
[8]
Luo H, Xie S, Ma C, Zhang W, Tschöpe C, Fa X, Cheng J, Cao J. Correlation Between Thymus Radiology and Myasthenia Gravis in Clinical Practice. Front Neurol. 2019 Jan 15;9:1173. doi: 10.3389/fneur.2018.01173. PMID: 30697185; PMCID: PMC6340958.
[9]
Chen J, Tian D-C, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. The Lancet Regional Health - Western Pacific. 2020;5(100063). https://doi.org/10.1016/j.lanwpc.2020.100063.
[10]
Lazaridis K, et al. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020 Feb 14;11:212. doi: 10.3389/fimmu.2020; 00212. Last accessed: June 2024.
[11]
Myasthenia Gravis Foundation of America (MGFA). Seronegative MG Resource Center. Available at: https://myasthenia.org/Newly-Diagnosed/Seronegative-MG-Resource-Center Last accessed: June 2024.
[12]
Jackson et al. Understanding the symptom burden and impact of myasthenia gravis from the patient’s perspective: A qualitative study. Neurology and Therapy. 2022;12:1; 107–128. Available at: https://doi.org/10.1007/s40120-022-00408-x.
[13]
Myasthenia Gravis Foundation of America (MGFA). Myasthenia Gravis Clinical Overview. Available at: https://myasthenia.org/Professionals/Clinical-Overview-of-MG#DIAGNOSTIC. Last accessed: June 2024
[14]
NHS. Myasthenia Gravis. Available at: https://www.nhs.uk/conditions/myasthenia-gravis/ Last accessed: June 2024.
[15]
NHS. Diagnosis Myasthenia Gravis. Available at: https://www.nhs.uk/conditions/myasthenia-gravis/diagnosis/ Last accessed: June 2024.